1.21
-0.05(-3.97%)
Currency In USD
| Previous Close | 1.26 |
| Open | 1.28 |
| Day High | 1.28 |
| Day Low | 1.2 |
| 52-Week High | 5.95 |
| 52-Week Low | 0.95 |
| Volume | 112,756 |
| Average Volume | 1.23M |
| Market Cap | 13.8M |
| PE | -0.92 |
| EPS | -1.32 |
| Moving Average 50 Days | 1.51 |
| Moving Average 200 Days | 2.01 |
| Change | -0.04 |
If you invested $1000 in Marker Therapeutics, Inc. (MRKR) 10 years ago, it would be worth $20.75 as of August 18, 2025 at a share price of $1.22. Whereas If you bought $1000 worth of Marker Therapeutics, Inc. (MRKR) shares 5 years ago, it would be worth $63.21 as of August 18, 2025 at a share price of $1.22.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Marker Therapeutics to Participate in a Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference
GlobeNewswire Inc.
Jul 30, 2025 12:00 PM GMT
HOUSTON, July 30, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and so
Marker Therapeutics and Cellipont Bioservices Announce Collaboration to Advance cGMP Manufacturing of MT-601, a Multi-Antigen Recognizing T Cell Therapy for Patients with Lymphoma
GlobeNewswire Inc.
Jun 17, 2025 12:00 PM GMT
HOUSTON, June 17, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and so
Marker Therapeutics Reports that Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients with Lymphoma
GlobeNewswire Inc.
May 20, 2025 12:00 PM GMT
Preconditioning with lymphodepletion linked to stronger MAR-T cells response and suggests enhanced anti-tumor activity Highest enrollment since study launch underscores momentum and signals a positive trial trajectory Clinical data readout from Phase